Therefore, it remains still unclear whether a therapeutic dose of Zol for the medical management of osteoporosis in postmenopausal women have anti-angiogenic effects, due to post-dose changes of VEGF, as previously recognized in cancer patients. Here, VEGFA is linked to osteoporosis.